There are conflicting data on the role of the lectin pathway of complement activation and its recognition molecules in acute rejection and outcome after transplantation. To help resolve this we analyzed polymorphisms and serum levels of lectin pathway components in 710 consecutive kidney transplant recipients enrolled in the nationwide Swiss Transplant Cohort Study, together with all biopsy-proven rejection episodes and 1-year graft and patient survival. Functional mannose-binding lectin (MBL) levels were determined in serum samples, and previously described MBL2, ficolin 2, and MBL-associated serine protease 2 polymorphisms were genotyped. Low MBL serum levels and deficient MBL2 diplotypes were associated with a higher incidence of acute cellular rejection during the first year, in particular in recipients of deceased-donor kidneys. This association remained significant (hazard ratio 1.75, 95% confidence interval 1.18-2.60) in a Cox regression model after adjustment for relevant covariates. In contrast, there was no significant association with rates of antibodymediated rejection, patient death, early graft dysfunction or loss. Thus, results in a prospective multicenter contemporary cohort suggest that MBL2 polymorphisms result in low MBL serum levels and are associated with acute cellular rejection after kidney transplantation. Since MBL deficiency is a relatively frequent trait in the normal population, our findings may lead to individual risk stratification and customized immunosuppression. 
T he innate immune system is primarily involved in natural immunity against pathogens and tissue injury. In the setting of solid-organ transplantation (SOT), experimental data have highlighted an important role of innate immune activation early after transplantation, in particular following donor brain death and during ischemia-reperfusion injury in the early stages after surgery. [1] [2] [3] Macrophages and dendritic cells act as immune sentinels in peripheral tissues and secondary lymphoid organs, regularly sampling and processing self-antigens to maintain immune homeostasis in steady-state conditions. These innate immune cells express pattern recognition receptors that specifically detect conserved pathogen-associated or danger-associated molecular patterns, in the context of local infection or sterile tissue damage, respectively. The activation of surface pattern recognition receptors results in the maturation of the cells into competent antigen-presenting cells that produce proinflammatory mediators and can initiate an adaptive immune response. [4] [5] [6] Besides surface-bound receptors, soluble pattern recognition receptors have been characterized, including complement-activating mannose-binding lectin (MBL) and ficolins (FCNs). 7 Upon ligation, the downstream MBL-associated serine protease (MASP) signaling activates the complement cascade.
MBL and FCN are mainly synthesized in the liver and function as oligomeric molecules assembled with MASP. In circulation, these oligomeric structures bind to surface carbohydrates of microbes and injured cells, leading to C3b-mediated opsonization and phagocytosis. Single-nucleotide polymorphisms (SNPs) in the genes encoding the lectin pathway proteins determine their functional activity and serum levels. 8 Due to prevalent genetic polymorphisms in both regulatory and coding sequences of MBL2, up to 25% of the normal population have reduced serum concentrations of MBL and can be classified as functionally deficient. 9 However, MBL functions may be redundant in healthy individuals, as low levels of functional MBL have been associated with susceptibility to infections mainly in immunocompromised individuals. [10] [11] [12] [13] As opposed to infectious settings, MBL deficiency has been described to be protective in some glomerular diseases such as IgA nephropathy, 14, 15 as well as in studies of kidney and heart transplantation where patients with low functional MBL serum levels had a better graft survival. [16] [17] [18] [19] Moreover, complement deficiency or blockade was shown to limit postischemic reperfusion injury in various organs, and protect against acute renal transplant rejection. [20] [21] [22] [23] [24] Conflicting data exist on the deleterious versus protective role of the lectin pathway of complement activation in graft rejection, as well as in patient and graft outcomes after SOT. [25] [26] [27] [28] Many of the available studies in kidney transplantation are either retrospective, involve small numbers of patients, or have analyzed outcomes under previous eras of immunosuppression and anti-infectious therapies. Therefore, the aim of the present study was to investigate the role of the lectin pathway of complement activation and the possible association between recipient genotype and graft outcomes after kidney transplantation in a large, well-characterized, ongoing prospective cohort. The primary end point was the incidence of biopsy-proven acute rejection episodes at 1 year after transplantation; secondary end points were deathcensored graft loss, graft function at 1 year, and patient survival.
RESULTS

Study population
Donor, recipient, and transplant baseline characteristics are described in Table 1 . Among the 710 consecutive Caucasian kidney transplant recipients included in the Swiss Transplant Cohort Study (STCS), 672 (94.6%) underwent a kidney-alone transplantation and 38 also received another organ, mainly pancreas (27/38) . One hundred twenty-four (17.5%) patients had a previous transplant, of whom 111 (15.6%) were undergoing kidney transplantation for a second or more time. Deceased donation provided the majority (59.4%) of the organs, with a median deceased donor age of 53 years and median cold ischemia time of 6.5 hours.
Patients were given induction and initial maintenance immunosuppression (prescribed within the first week after transplantation) based on international and local guidelines, according to their immunologic risk status. Basiliximab was used in 62.1% of patients, 18.3% received anti-thymocyte globulin, and in 19.6% no induction was prescribed. Steroids and mycophenolic acid-based agents were used in >86% of the patients. Calcineurin inhibitors were started early in 76.7% of the recipients, with a large preference for tacrolimus (FK) as compared to cyclosporine.
Serum MBL levels in kidney transplant recipients correlated with genotypes
The overall median MBL2 serum level measured on the day of transplantation was 678.2 ng/ml (Figure 1 ). Patients were classified as having "high" (> median) and "low" (# median) MBL levels. The latter group was further stratified into "intermediate" ($10 ng/ml) or "deficient" (<10 ng/ml) MBL levels. As shown in Figure 1 , MBL serum levels were largely dependent on the MBL2 genotype in our study population. The YAYA and YAXA diplotypes resulted in the higher serum MBL levels and were the main genotypes found in our population (total 401 patients, 56.6%) as compared to the remaining XAXA, YAYO, and XAYO (total 266 patients, 37.6%) and YOYO (total 41 patients, 5.8%) diplotypes, which were associated with intermediate and deficient MBL serum levels, respectively. These data obtained from pretransplant end-stage renal disease patients were in accordance with previous reports in the general population, describing the correlation between the selected SNPs and functional MBL serum levels. 8 Polymorphisms in MBL2 resulting in low MBL serum levels are associated with an increased risk of acute cellular rejection in the first year after transplantation
The 12-month cumulative incidence of biopsy-proven acute cellular rejection (ACR) and antibody-mediated rejection (AMR) was 0.20 and 0.05, respectively. A total of 144 ACR episodes were recorded during the first year, of which 122 had occurred during the first 6 months after transplantation. Among the cohort of patients (n ¼ 473) who reached the 3-year follow-up, the incidence of ACR declined over time, with only 16 new ACR episodes reported after the first year. Within the ACR episodes during the first year, 7 were histologically classified as borderline tubulitis. During the first year after transplantation, 32 AMR episodes occurred in our study population. Overall, little modification was made in maintenance immunosuppression during the first year as compared to initial therapy. The majority of patients were still on a combination therapy of calcineurin inhibitors (97%, including 76% under FK) and mycophenolic acid-based agents (87%), and 73% received steroids at the 12-month follow-up. The same trend was observed at subsequent yearly follow-up analysis, with, interestingly, still 58% and 50% of patients maintained on steroid treatment at 2 and 3 years after transplantation, respectively. Low MBL serum levels (# median) were significantly associated with the risk of developing ACR during the first year after transplantation (log-rank test ¼ 0.01, Figure 2a ).
The effect of MBL serum levels on ACR episodes was confirmed when analyzing the data based on MBL2 genotypes (Figure 2b ). This was even more striking when we stratified into "high" versus "intermediate" and "deficient" MBL serum levels ( Figure 2c ) and corresponding "YAYA" or "YAXA" versus "XAYO," "YAYO," or "XAXA" and "YOYO" diplotypes ( Figure 2d) . In univariate analysis, the other factors negatively influencing the risk of ACR included donor age and donorrecipient human leukocyte antigen (HLA) mismatches ( Table S1 ). Data analysis excluding the subgroup of patients with borderline tubulitis yielded similar results (Supplementary Figure S1 , Supplementary Tables S2  and S3 ). There was no association between either MBL serum levels or MBL2 diplotypes and the cumulative incidence of AMR during the first year after transplantation (data not shown).
Ficolins and MASP are other important components of the lectin pathway, and their serum concentrations were previously shown to correspond to polymorphisms in the respective FCN2 and MASP2 genes. 29 We did not find any significant association between the investigated SNPs and ACR in our study population, except for a trend toward a deleterious effect of the FCN2 rs7851696 SNP (HR 1.39, 95% CI 0.97-2.00, P ¼ 0.07). This, however, did not reach statistical significance in the multivariable analysis.
Patient and early graft outcome after kidney transplantation From our starting cohort of 710 patients, 666 patients were followed for at least 1 year, 638 patients for up to 24 months after transplantation, and 473 patients reached the 3-year follow-up time. At 3 years, a total of 22 patients had lost their kidney graft (13 during the first year), and 42 died with a functioning graft (23 during the first year). Table 3 summarizes the risk factors for death at 1 year after transplantation. The MBL status at the time of transplantation did not have a Correlation between MBL2 levels and MBL2 diplotypes was measured by analysis of variance and non-parametric Kruskal-Wallis rank test (P < 0.001).
significant impact on short-term patient survival, nor FCN2 and MASP2 genotypes. In the multivariable analysis, donor male gender was significantly associated with death (HR 3.76, 95% CI 1.24-11.4, P ¼ 0.02) as well as recipient age (HR 2.22, 95% CI 1.42-3.47, P < 0.001), while immunosuppressive regimens with calcineurin inhibitors or mycophenolic acidbased agents were protective. We next analyzed deathcensored graft loss after transplantation (Table 4) and found a strong association with rejection episodes during the first year (HR 6.21, 95% CI 2.71-14.2, P < 0.002), as well as with recipient age (HR 2.04, 95% CI 1.48-2.81, P < 0.001), and a trend toward association with the MASP2 rs12085877 SNP (HR 2.90, 95% CI 0.85-9.95, P ¼ 0.09), but not with MBL2 or FCN2 polymorphisms. Overall, while the low MBL status was associated with ACR, there was no direct association with patient death or graft loss at 1 year in the uni-and multivariable analysis. Analysis of the cohort of patients that reached 3 years follow-up corroborated the results on patient and graft survival obtained at 1 year (data not shown).
Because graft function at 1 year is an important predictor of long-term graft and patient survival after kidney transplantation, 30, 31 we analyzed renal function at 1 year and stratified the patients according to estimated glomerular filtration rate values, setting a cutoff value of 40 ml/min per 1.73 m 2 to account for moderate to severe graft dysfunction. As shown in Table 5 , graft dysfunction was strongly associated with rejection episodes (ACR and AMR) during the first year (HR 4.96, 95% CI 2.76-8.91, P < 0.001), as well as with donor age (HR 2.04, 95% CI 1.59-2.61, P < 0.001), and borderline associated with cyclosporine-based maintenance immunosuppression (HR 2.04, 95% CI 1.00-4.19, P ¼ 0.051). The MBL status did not directly affect graft function at 1 year in our study.
DISCUSSION
Over the past years, inconsistent experimental and clinical data have been reported regarding the role of the lectin pathway of complement activation in graft and recipient outcomes after SOT. Using the large prospective multicenter STCS database, we investigated the associations between previously described SNPs in the lectin pathway of complement activation and outcome after kidney transplantation. The top panels show stratification into 2 groups, according to MBL2 serum levels (across median, a) or MBL2 diplotypes (high-level diplotypes "YAYA" or "YAXA" vs. low-level diplotypes "XAXA," "YAYO," "XAYO," or "YOYO," b). In order to account for MBL2 deficiency, the 2 lower panels show stratification into 3 groups, according to MBL2 serum levels ("high" vs. "intermediate" and "deficient" levels, c) and diplotypes (high-level "YAYA" or "YAXA" vs. intermediate "XAYO," "YAYO," or "XAXA" and deficient "YOYO" diplotypes). P values stand for the log-rank test. Patients receiving multiple organs were included except 10 kidney/liver recipients. Mannose-binding lectin (MBL) genotyping was missing in 2 of 710 patients, and MBL levels were missing in 1 of 710 patients.
c l i n i c a l i n v e s t i g a t i o n D Golshayan et al.: Lectin pathway and rejection after transplantation
Our main finding was that MBL2 genotypes resulting in low MBL serum levels strongly correlated with the incidence of ACR in the first year after transplantation. This effect was still observed when analyzing the data at 36 months (data not shown) and was a more potent predictor of ACR than differences in immunosuppressive regimens or other traditional risk factors as documented in multivariable analyses. Interestingly, when stratifying the 144 ACR episodes during the first year according to histologic severity (70 tubulointerstitial/Banff I, 74 vascular/Banff II and III), ) , B (G54D, rs1800450), and C (G57E, rs1800451), respectively, and the wild-type allele of each is referred to as genotype A. MBL genotype Y refers to presence of rare variant C of promoter SNP G221C (rs7096206) and genotype X as wild-type allele G of that polymorphism. d P value after correction for multiple testing (N ¼ 10) is 0.1. e P value after correction for multiple testing (N ¼ 10) is 0.7. f Multivariable analysis was performed by using stepwise regression model. The proportional hazards assumption was tested by using the stphtest command implemented in Stata. No deviation from this assumption was observed for MBLs. However, since 2 covariables in the multivariable model did not verify this hypothesis (basiliximab, P ¼ 0.0001; steroids, P ¼ 0.05), those were accounted for by using a stratified multivariable Cox model. Final global proportional hazards assumption test P value for multivariable Cox model was 0.84. In addition we have performed univariate and multivariable stepwise logistic regression analysis for ACR at 1 year after transplantation to account for those variables (Supplementary Table S1 ).
D Golshayan et al.: Lectin pathway and rejection after transplantation c l i n i c a l i n v e s t i g a t i o n
Kidney International (2016) 89, 927-938 a significant correlation was found only between low MBL status and tubulointerstitial ACR (Supplementary Figures S2  and S3 ). Besides low MBL serum levels, the other significant independent risk factors for ACR were donor age and HLA mismatches, as previously described. 32 Registry data have highlighted the efficacy of current immunosuppressive regimens in preventing acute rejection, in particular ACR, at least in low-immunologic-risk recipients. [33] [34] [35] Interestingly, these immunosuppressive treatments were developed to target adaptive immune responses, but they only marginally affect innate immunity. Thus, the potential protective role of MBL in preventing ACR may have been better unraveled when 
adaptive immunity was under check by current potent immunosuppressive regimens such as in the present study. Previous reports either did not find a significant association between MBL status and acute rejection 36 or concentrated on long-term graft and patient outcomes. 16, 17, 26 The finding of robust and clear-cut association between low MBL status and increased incidence of ACR seen in our study is likely due to size and homogeneity of the prospectively followed cohort being treated with recent-era immunosuppressive protocols. Moreover, the relatively homogeneous drug prescription, in ) , B (G54D, rs1800450), and C (G57E, rs1800451), respectively, and the wild-type allele of each is referred to as genotype A. MBL genotype Y refers to presence of rare variant C of promoter SNP G221C (rs7096206) and genotype X as wild-type allele G of that polymorphism. d P value after correction for multiple testing (N ¼ 10) is 0.7. e P value after correction for multiple testing (N ¼ 10) is 0.9. f Multivariable analysis was performed by using stepwise regression model. The proportional hazards assumption was tested by using the stphtest command implemented in Stata. In this model no violation from the proportional hazards assumption was observed. Final global proportional hazards assumption test P value for multivariable Cox model was 0.39.
Kidney International (2016) 89, 927-938 particular regarding maintenance treatment during the first year, may have unmasked the effects of innate immunity, such as the MBL pathway of the complement system.
The lectin pathway of complement activation plays an important role in host defenses against microorganisms, and unambiguous data exist on the harmful role of low MBL levels in the incidence and severity of bacterial, viral, and fungal infections after transplantation. 13, 37, 38 Indeed, local complement activation via the lectin pathway leads to the production of C3b that mediates opsonization and 39, 40 This leads to the formation of C3 convertase and downstream complement cascade activation, resulting in the local production of the terminal component C5b-C9 (membrane attack complex) that contributes to tissue damage. Accordingly, inhibition of MBL using a monoclonal antibody resulted in reduced cardiac damage in a rat model of myocardial ischemia-reperfusion. 41 Recently, data from experimental models of renal ischemia-reperfusion injury suggested an additional direct cytotoxic effect of circulating MBL on tubular epithelial cells. 42 Thus, high MBL serum levels may be deleterious in the setting of severe ischemia-reperfusion injury early after SOT, as well as contribute to delayed graft function. Organs or tissues may, however have different susceptibilities to ischemia-reperfusion injury, therefore be differentially affected by MBL serum levels, in part explaining some discrepancies on the reported role of this pathway in various experimental and clinical settings and across organs. In our cohort, up to 40% of the kidneys came from living donors, and, even for deceased donors, the median cold ischemia time was relatively short (reflecting the small distances between centers in Switzerland). Unfortunately, we could not investigate delayed graft function appropriately using the STCS database. However, the fact that our cohort possibly experienced less initial graft damage may in part explain why we did not find a significant association between MBL serum levels and graft dysfunction or loss at 1 year, as opposed to some studies which preponderantly included deceased donors. 16, 17 Besides its role in host defenses against pathogens, MBL was shown to directly bind to late apoptotic and necrotic cells in vitro, facilitating phagocytosis by macrophages and dendritic cells. 43, 44 These findings indicate a role of the lectin pathway in tissue homeostasis and immune tolerance. Low MBL serum levels have been associated with autoimmune diseases such as systemic lupus erythematosus or rheumatoid arthritis. 12, [45] [46] [47] [48] In a recent study in SOT, early surveillance biopsies performed at 3 to 6 months after kidney transplantation were analyzed for the degree of inflammation and cell death in the tubulointerstitial compartment. The authors concluded that low recipient serum MBL levels were associated with increased inflammation and apoptosis. 49 Interestingly and in line with our data, the same authors had previously described that subclinical rejection after kidney transplantation was associated with low serum MBL levels. 50 Thus, depending on the microenvironment, MBL may exert a protective or a deleterious role, and this could partly explain the discrepancies observed in various experimental and clinical studies. By binding to injured tissues in the acute inflammatory setting of ischemia-reperfusion injury after transplantation, MBL would aggravate tissue damage and potentiate alloantigen presentation. In the absence of overt inflammation, such as at later stages after transplantation, MBL could contribute to the sequestration and clearance of graft-derived apoptotic cells by quiescent immature macrophages and dendritic cells, thus limiting host alloresponses.
c l i n i c a l i n v e s t i g a t i o n
The activation of the lectin pathway leads to the formation of C3 convertase and the downstream complement cascade, resulting in the production of membrane attack complex. This pathway may thus be implicated in endothelial injury and AMR. However, we did not find any association between MBL serum levels and AMR, but our study was limited by relatively low numbers of events during the first year. While the lectin pathway may contribute to its pathogenesis, the initiation of AMR is probably more dependent on the presence of circulating donor-specific alloantibodies and the activation of the classical pathway of complement.
The MBL status at the time of transplantation did not have a significant direct impact on patient and graft 1-and 3-year survival as well as on 1-year graft function in our prospective study, nor FCN2 and MASP2 genotypes. In fact, acute rejection episodes and in particular ACR were the most important determinants of graft outcome after transplantation in our multivariable analysis (Tables 4 and 5 , data not shown at 3 years). Recently, Bay et al. have used a lower median cutoff value (#454 ng/ml) and have shown that low serum MBL levels were associated with decreased 5-year death-censored graft survival. 26 Interestingly, the strongest association was seen in non-immunized patients receiving a kidney from a deceased donor. 26 When stratifying our data, we also observed a strongest association between low MBL status and ACR in recipients of deceased as compared to living donors (Supplementary Figures S4 and S5) . These results supported the concept of MBL being involved in the clearance of graftderived damaged and dying cells, a process that would be more needed in the context of cadaveric organs and prolonged cold ischemia time to limit host alloreactivity. On the other hand, our results are in contradiction with studies from Berger et al., who found that low pretransplant MBL serum levels (<400 mg/ml) were protective for patient and graft survival. 16, 17 However, these studies were performed in smaller cohorts and in previous eras using other immunosuppressive regimens. Moreover, with longer follow-up periods (>10 years in these studies), other non-immunologic confounders may have been involved. Indeed, low MBL serum levels were also shown in the general population to be associated with accelerated atherosclerosis, 51 a major risk factor for patient and graft loss after transplantation.
In conclusion, using the large and well-characterized contemporary prospective STCS cohort, we found that low MBL serum levels at the time of transplantation were associated with an increased risk of ACR after kidney transplantation, in particular in recipients of deceased donors. As acute rejection episodes were predictors of worse graft outcome after kidney transplantation, our findings are potentially important and they should be confirmed in other prospective cohorts and studied for other solid organs. MBL deficiency being a relatively frequent trait in the normal population, screening and MBL substitution could be 
MATERIALS AND METHODS Study design
The STCS is a prospective multicenter cohort including all SOT activity performed in Switzerland from May 2008 onward. 52 The overall acceptance rate of participation in the STCS is 95%. For this study, we included all Caucasian consecutive kidney transplant recipients transplanted from May 2008 to March 2011. The STCS has been approved by the ethics committees of all centers, and all patients have given written informed consent for participation.
Data collection
Patient-and transplant-specific data were collected at baseline (day of transplantation), then prospectively at 6 and 12 months, and yearly after using standardized case report forms. Baseline donor and recipient data included gender, age, ethnicity, diagnostic of nephropathy, preexisting comorbidities, and HLA immunologic status. Transplant-related data included type of donor, cold ischemia time, and immunosuppressive induction treatment. Follow-up data included graft loss, patient outcome, weight, serum creatinine, immunosuppressive treatments, rejection episodes, and infectious and noninfectious events (mainly cardiovascular and oncologic). All biopsies (per protocol and per cause) were recorded in the STCS database and scored according to Banff '09 update classification 53 by each center's reference pathologist. For our study, we classified the rejection episodes as follows: biopsy-proven acute cellular rejection (ACR) regrouping borderline changes and acute T cell-mediated rejection, and acute and chronic active humoral rejection grouped as antibody-mediated rejection (AMR). Cytomegalovirus events were classified as either asymptomatic replication (viremia) or disease (replication with corresponding signs/symptoms). [54] [55] [56] Cytomegalovirus antiviral strategies depended on donor-recipient serostatus but varied among centers, using either a 3-to 6-month prophylactic strategy or a preemptive polymerase chain reaction screening approach. 55 Polyomavirus BK occurrences were classified as viremia or probable/proven disease (viremia > 10,000 copies twice, biopsyproven nephropathy, or both).
Study end points
The primary end point was the incidence of biopsy-proven acute rejection at 1 year after transplantation. As secondary end points, we assessed patient and death-censored graft loss (defined as need for dialysis or retransplantation), and graft function at 1 year as estimated by the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) formula.
DNA extraction and genotyping DNA was extracted from blood samples collected from each patient at the time of transplantation, as described. 57 To limit the risk of population stratification bias, genetic analyses were performed in Caucasian patients only. Candidate gene genotyping was performed using a custom-made genotyping platform (VeraCode GoldenGate Genotyping Assay on BeadXpress, Illumina, San Diego, CA) or competitive allele-specific PCR (KASP) technology (LGC Genomics, Teddington, UK). 57 Based on previous literature, the following 6 SNPs in the MBL2 gene were selected for analysis: rs5030737, rs11003125, rs1800450, rs1800451, rs7095891, and rs7096206. The following 4 SNPs were assessed for the FCN2 gene: rs7851696, rs17514136, rs3124953, and rs3124952; and 3 for the MASP2 gene: rs56392418, rs12085877, and rs1033638. To check for genotyping accuracy, Hardy-Weinberg equilibrium and pairwise linkage disequilibrium were calculated with the genhwi and the pwld programs in Stata 13.1 software (StataCorp, College Station, TX). SNP frequencies and linkage disequilibrium were compared to those found in general Caucasian population (from public genetic databases such as HapMap Project or 1000 Genomes Project). MBL haplotypes were inferred using PHASE 2.1 software (University of Washington, Seattle, WA). MBL genotype O was defined as presence of rare allele D (R52C, rs5030737) , B (G54D, rs1800450), and C (G57E, rs1800451), respectively. Presence of the wild-type allele of each was referred to as genotype A. MBL genotype Y was defined as presence of rare variant C of promoter SNP G221C (rs7096206) and genotype X as wild-type allele G of that polymorphism.
MBL serum levels A serum sample was obtained on the day of transplantation from 710 consecutive Caucasian kidney transplant recipients enrolled in the STCS for the determination of functional MBL levels by enzymelinked immunosorbent assay (MBL Oligomer ELISA Kit, Bioporto Diagnostics, Hellerup, Denmark).
Statistical analysis
Statistical analyses were performed by using Stata 13.1 software. Associations were assessed by using the log-rank test and in multivariable stepwise Cox regression models for covariates that were independently associated with each end point, with censoring at death or lost to follow-up date at 12 or 36 months post-transplantation. The P value of 0.05 was considered to be significant. The proportional hazards assumption was tested by using stphtest and stcoxkm programs in Stata 13.1 software after fitting a Cox model. For variables that showed violation of the proportional hazards assumption, we performed a stratified Cox model by using the strata option in Stata. The incidence (time to first rejection episode) and type of rejection were analyzed according to genotypes as categorical variables, as well as according to MBL functional levels as continuous variables. Correlation between MBL2 levels and MBL2 diplotypes was measured by a 1-way analysis of variance and non-parametric Kruskal-Wallis test. Other previously described determinants of rejection and graft outcome were considered as relevant covariates in multivariable analysis. In particular, immunosuppressive drugs were considered in a time-dependent manner, accounting for all changes during follow-up.
DISCLOSURE
All the authors declared no competing interests. Figure S1 . One-year cumulative incidence of acute cellular rejection according to MBL2 levels and MBL2 diplotypes in kidney transplant recipients, excluding borderline tubulitis. The top panels show stratification into 2 groups, according to MBL2 serum levels (across median, A) or MBL2 diplotypes (high-level diplotypes "YAYA" or "YAXA" vs. lowlevel diplotypes "XAXA," "YAYO," "XAYO," or "YOYO," B). In order to account for MBL2 deficiency, the 2 lower panels show stratification into 3 groups, according to MBL2 serum levels ("high" vs. "intermediate" and "deficient" levels, C) and diplotypes (high-level "YAYA" or "YAXA" vs. intermediate "XAYO," "YAYO," or "XAXA" and deficient "YOYO" diplotypes). P values stand for the log-rank test. Figure S2 . One-year cumulative incidence of tubulointerstitial acute cellular rejection according to MBL2 levels and MBL2 diplotypes in kidney transplant recipients. The top panels show stratification into 2 groups, according to MBL2 serum levels (across median, A) or MBL2 diplotypes (high-level diplotypes "YAYA" or "YAXA" vs. low-level diplotypes "XAXA," "YAYO," "XAYO," or "YOYO," B). In order to account for MBL2 deficiency, the 2 lower panels show stratification into 3 groups, according to MBL2 serum levels ("high" vs. "intermediate" and "deficient" levels, C) and diplotypes (high-level "YAYA" or "YAXA" vs. intermediate "XAYO," "YAYO," or "XAXA" and deficient "YOYO" diplotypes). P values stand for the log-rank test. Patients receiving multiple organs were included except 10 kidney/ liver recipients. Figure S3 . One-year cumulative incidence of vascular acute cellular rejection according to MBL2 levels and MBL2 diplotypes in kidney transplant recipients. The top panels show stratification into 2 groups, according to MBL2 serum levels (across median, A) or MBL2 diplotypes (high-level diplotypes "YAYA" or "YAXA" vs. low-level diplotypes "XAXA," "YAYO," "XAYO," or "YOYO," B). In order to account for MBL2 deficiency, the 2 lower panels show stratification into 3 groups, according to MBL2 serum levels ("high" vs. "intermediate" and "deficient" levels, C) and diplotypes (high-level "YAYA" or "YAXA" vs. intermediate "XAYO," "YAYO," or "XAXA" and deficient "YOYO" diplotypes). P values stand for the log-rank test. Patients receiving multiple organs were included except 10 kidney/liver recipients. Figure S4 . One-year cumulative incidence of acute cellular rejection according to MBL2 levels and MBL2 diplotypes in 422 kidney recipients from deceased donors. The top panels show stratification into 2 groups, according to MBL2 serum levels (across median, A) or MBL2 diplotypes (high-level diplotypes "YAYA" or "YAXA" vs. low-level diplotypes "XAXA," "YAYO," "XAYO," or "YOYO," B). In order to account for MBL2 deficiency, the 2 lower panels show stratification into 3 groups, according to MBL2 serum levels ("high" vs. "intermediate" and "deficient" levels, C) and diplotypes (high-level "YAYA" or "YAXA" vs. intermediate "XAYO," "YAYO," or "XAXA" and deficient "YOYO" diplotypes). P values stand for the log-rank test. Patients receiving multiple organs were included except 10 kidney/liver recipients. MBL levels were missing in 1 of 710 patients. Figure S5 . One-year cumulative incidence of acute cellular rejection according to MBL2 levels and MBL2 diplotypes in 288 kidney recipients from living donors. The top panels show stratification into 2 groups, according to MBL2 serum levels (across median, A) or MBL2 diplotypes (high-level diplotypes "YAYA" or "YAXA" vs. low-level diplotypes "XAXA," "YAYO," "XAYO," or "YOYO," B). In order to account for MBL2 deficiency, the 2 lower panels show stratification into 3 groups, according to MBL2 serum levels ("high" vs. "intermediate" and "deficient" levels, C) and diplotypes (high-level "YAYA" or "YAXA" vs. intermediate "XAYO," "YAYO," or "XAXA" and deficient "YOYO" diplotypes). P values stand for the log-rank test. MBL genotyping was missing in 2 of 288 patients. Table S1 . Predictors of ACR at 1 year after transplantation (logistic regression analysis). Table S2 . Risk factors for acute cellular rejection excluding borderline tubulitis at 1 year after transplantation. Table S3 . Predictors of ACR excluding borderline tubulitis at 1 year after transplantation (logistic regression analysis). Supplementary material is linked to the online version of the paper at www.kidney-international.org.
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